Highlights Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-16 EDT			5-day change	1st Jan Change
0.7836 ^USD	-0.18%		+13.57%	-46.33%

04-25	Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	CI
01-12	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	04-25	CI
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	01-12	CI
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	12-21	CI
Virax Biolabs Group Limited Signs Contracts to Launch Two New Research and Laboratory Facilities in the United Kingdom	23-07-18	CI
Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-14	CI
Virax Biolabs Group Limited Announces Establishment of Regional Headquarters at Dubai Science Park	23-05-04	CI
Virax Biolabs Group Limited Enters into an Agreement for the Distribution of Marburg Virus PCR Testing Kits	23-04-19	CI
Virax Biolabs Signs Agreement to Distribute Avian Influenza A Virus Test Kit in the European Union; Shares Surge Pre-Bell	23-03-07	MT
Virax Biolabs Group Limited Enters into an Agreement for the Distribution of an Avian Influenza A Virus	23-03-07	CI
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health	23-02-07	CI
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health	23-02-07	CI
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2022	23-02-02	CI
Virax Biolabs Introduces Human Papillomavirus Test Kit	23-01-04	CI
Virax Biolabs Says US FDA Grants Emergency Use Authorization for COVID-19 Rapid Antigen Test	22-12-06	MT
Virax Biolabs Group Limited Receives Emergency Use Authorization in the United States	22-12-06	CI
Virax Biolabs Introduces RSV-Influenza-Covid Triple Virus Antigen Rapid Test Kit	22-11-03	CI
Virax Biolabs Group Limited Announces Initiation of Its Virax Immune COVID-19 Analytical Performance Study	22-10-26	CI
Cosmos Health Signs an Agreement with Virax Biolabs to Distribute Monkeypox Virus Real-Time PCR Detections Kits in Europe	22-09-22	CI
Virax Biolabs, Cosmos Holdings Enter Into Monkeypox Test Distribution Agreement; Shares Rise Pre-Bell	22-09-22	MT
Virax Biolabs Group Limited Announces Distribution Agreement with Cosmos Holdings Inc. to Market Monkeypox Virus Real-Time Pcr Detection Kit	22-09-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Highlights

Filters